TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04271579

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Salvage Lymphnode dissection
Description: A salvage lymphnode dissection is performed in all study patients (both arms)using standard surgical techniques (openly or DaVinci).In patients who were randomized to the bilateral pelvic lymphnode dissection group, a salvage lymphadenectomy was also performed on the opposite side with resection of the corresponding fields that were removed on the PSMA-PET positive side (th Blinding must be guaranteed during pathological assessment)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Salvage Lymphnode dissection
Description: A salvage lymphnode dissection is performed in all study patients (both arms)using standard surgical techniques (openly or DaVinci).In patients who were randomized to the bilateral pelvic lymphnode dissection group, a salvage lymphadenectomy was also performed on the opposite side with resection of the corresponding fields that were removed on the PSMA-PET positive side (th Blinding must be guaranteed during pathological assessment)
Study: NCT02140411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab Intravitreal injections
Description: Ranibizumab intravitreal injections 3 months 1 per month and after PRN treatment.
Study: NCT03946553

Intervention type: OTHER
Description: No intervention
Study: NCT03357835

Intervention type: OTHER
Intervention: Trauma Decision System
Description: At the time of application, color codes indicating the urgency of the patients will be given according to the demographic data of the patients, the type of trauma and the vital signs were directed by the software program. As a result of the software program's direction, patients will be coded as green-yellow-orange-red area and patient care will be made in accordance with these codes.
Study: NCT01892683

Intervention type: DRUG
Intervention: General anesthesia with propofol
Description: Study subjects will undergo general anesthesia with propofol according to the clinical standard protocol practiced at the hospital of the University of Munich.
Study: NCT04229368

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D will be given at doses commonly given to patients with low vitamin D levels

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D will be given at doses commonly given to patients with low vitamin D levels
Study: NCT01498770

Intervention type: DRUG
Intervention: Zotepine
Description: Zotepine prescribed as recorded in the CPRD in the UK
Study: NCT00790894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ixabepilone
Description: Arm A: ixabepilone will be given at a dose of 40 mg/m2 as a 3-hour intravenous infusion on Day 1 in a 21 days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Arm B: ixabepilone will be given at a dose of 20 mg/m2 as a 3-hour intravenous infusion on Days 1, 8 and 15, then 1 week off in a 28-days cycle.
Study: NCT00150813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Pharmaceutical form: oral tablets Route of administration: Oral use
Study: NCT03425747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Citrate
Description: subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Citrate
Description: subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
Study: NCT01499056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem cell injection
Description: intra articular inection of mesenchymal stem cell
Study: NCT02336971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCT for PTSD
Description: CBCT consists of three phases of treatment: Phase 1: treatment orientation and education about PTSD and its related intimate relationship problems Phase 2: behavioral communication skills training Phase 3: cognitive interventions based on Cognitive Processing Therapy (CPT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: PE consists of: psychoeducation and some limited distress management training, but emphasizes the role of imaginal and in vivo exposure in treating PTSD.
Study: NCT02457260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14 N Sodium Nitrite
Description: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14 N Sodium Nitrite
Description: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14 N Sodium Nitrite
Description: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks
Study: NCT03217331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRD-102
Description: 14 mg CRD-102 capsules administered twice daily orally for 14 days.
Study: NCT03624972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Starting the Conversation Video
Description: The Starting the Conversation program is designed to increase self-efficacy and outcome expectancies for communicating with providers about sexual health and related issues, reduce barriers to communication, and provide basic training in skills for communicating with providers about these topics, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual and Menopausal Health Resources
Description: Patients will receive a resource list that includes both web-based resources on menopausal and sexual health and center-specific resources, such as contact information for a menopausal \& sexual health clinic.
Study: NCT01332955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Drug : telaprevir, Tablet, Oral, 750 mg, q8h, 12 weeks if associated with atazanavir or raltegravir~Drug : telaprevir, Tablet, Oral, 1125 mg, q8h, 12 weeks if associated with efavirenz

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegIFN alfa-2a
Description: Subcutaneous injection, 180 μg, once weekly, 48 weeks or 72 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: (weight-based dose) Tablet, Oral, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, 48 weeks or 72 weeks
Study: NCT03706456

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Darvadstrocel
Description: Darvadstrocel cell suspension for intralesional injection.
Study: NCT03624972

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sexual and Menopausal Health Resources
Description: Patients will receive a resource list that includes both web-based resources on menopausal and sexual health and center-specific resources, such as contact information for a menopausal \& sexual health clinic.
Study: NCT00928304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetaben (BAY94-9172)
Description: 300 megabecquerels (MBq) as single IV injection of 2 to 10 mL
Study: NCT03581799

Intervention type: OTHER
Group type: OTHER
Intervention: Oral dispersible tablet
Description: Administration of a 5 mm calcium carbonate based ODT placed in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
Study: NCT03246711

Intervention type: BEHAVIORAL
Intervention: Fasting
Description: Totally or partially fasting the holy month of ramadan for muslims

Intervention type: BEHAVIORAL
Intervention: Fasting
Description: Totally or partially fasting the holy month of ramadan for muslims
Study: NCT01936597

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic and preventive strategies
Description: Single set (control Arm)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic and preventive strategies
Description: Controller

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic and preventive strategies
Description: Audio
Study: NCT03899571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir Oral Capsule for 5 days post-exposure
Description: Patients will receive oseltamivir for 5 days after last influenza exposure.
Study: NCT01392768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Oral solution (Each mL contains 100mg of levetiracetam) or immediate-release tablets (Tablets containing 500mg or 1000mg of levetiracetam)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, properly standardized to suit the characteristics of each dosage form (oral solution and tablets) of levetiracetam
Study: NCT02031757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perturbation training
Description: training utilizing a system that provides small, controlled and unpredictable perturbations during treadmill walking.
Study: NCT03899571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir Oral Capsule for 10 days post-exposure
Description: Patients will receive oseltamivir for 10 days after last influenza exposure.
Study: NCT00316849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally
Study: NCT03889444

Intervention type: DRUG
Intervention: Dexamethasone intravitreal implant
Description: Dexamethasone intravitreal implant 0.7 mg injection, as per routine clinical practice.
Study: NCT00598988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traditional Chinese acupuncture
Description: 10 treatments over 6 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard medical care
Description: standard care as provided by primary physician
Study: NCT01202292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral (e.g., Psychotherapy, Lifestyle Counseling)
Description: Group motivational intervention consist in expert psychologist 32 monthly sessions (group intervention) on top of the diet plus exercise
Study: NCT03054441

Intervention type: OTHER
Intervention: Actigraph
Description: Actigraphs worn on wrists

Intervention type: OTHER
Intervention: Actigraph
Description: Actigraphs worn on wrists
Study: NCT02962284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate with Methylprednisolone
Description: YONSA 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
Study: NCT03259269

Intervention type: OTHER
Intervention: This is a non-intervention observational study
Description: No applicable intervention; this is a secondary data analysis observational study.

Intervention type: OTHER
Intervention: This is a non-intervention observational study
Description: No applicable intervention; this is a secondary data analysis observational study.
Study: NCT01365598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Single dose of oral primaquine phosphate. Comparator dose is 0.75mg/kg primaquine base. Each experimental arm is a different (reduced) dose of primaquine phosphate. Placebo contains no primaquine phosphate (non-active ingredients only).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Single dose of oral primaquine phosphate. Comparator dose is 0.75mg/kg primaquine base. Each experimental arm is a different (reduced) dose of primaquine phosphate. Placebo contains no primaquine phosphate (non-active ingredients only).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Primaquine
Description: Single dose of oral primaquine phosphate. Comparator dose is 0.75mg/kg primaquine base. Each experimental arm is a different (reduced) dose of primaquine phosphate. Placebo contains no primaquine phosphate (non-active ingredients only).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Single dose of oral primaquine phosphate. Comparator dose is 0.75mg/kg primaquine base. Each experimental arm is a different (reduced) dose of primaquine phosphate. Placebo contains no primaquine phosphate (non-active ingredients only).
Study: NCT02031757

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balance exercises
Description: specific exercises regularly used in rehabilitation aiming to improve balance
Study: NCT04568876

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension
Description: Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes
Study: NCT03238261

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemotherapy and concomitant radiotherapy
Description: Radiotherapy (teletherapy + high or low rate brachytherapy)
Study: NCT04568876

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Standard Therapy
Description: Standard therapy established for individual patients

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Standard therapy established for individual patients
Study: NCT01651234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCC-4401
Description: * Swedish Orange opaque hard gelatin capsules of size 1 with no markings for oral use~* single dose~* dosage~  * Cohort 1: 2.5-mg GCC-4401C~ * Cohort 2: 5.0-mg GCC-4401C~ * Cohort 3: 10-mg GCC-4401C~ * Cohort 4: 20-mg GCC-4401C~ * Cohort 5: 40-mg GCC-4401C~ * Cohort 6: 80-mg GCC-4401C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GCC-4401C
Description: * Capsule, identical in appearance to GCC-4401C, for oral use~* single dose~* dosage~  * Cohort 1: 2.5-mg matching placebo~ * Cohort 2: 5.0-mg matching placebo~ * Cohort 3: 10-mg matching placebo~ * Cohort 4: 20-mg matching placebo~ * Cohort 5: 40-mg matching placebo~ * Cohort 6: 80-mg matching placebo
Study: NCT00736606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: One single dose of 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9056 + simvastatin
Description: AZD9056: 400 mg od, 8 days simvastatin: one single dose of 40 mg on day 7
Study: NCT00126425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123I-mIBG (meta-iodobenzylguanidine)
Description: Single dose
Study: NCT01102959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photographic Educational Material
Description: Photographic Educational Material on Carbohydrate Counting
Study: NCT02784275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclo-Z

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclo-Z

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclo-Z

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00970060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
Study: NCT03207230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardea SOLO
Description: Participants will be asked to wear everyday for 7 days after the Baseline visit. the monitor attaches to the skin with adhesive and records heart rate and heart rhythm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiGraph wGT3X-BT
Description: Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable tracks activity and the step count during the day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wavelet Wristband
Description: Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable measures the activity and the heart rate as measured by PPG sensor.
Study: NCT03194607

Intervention type: OTHER
Intervention: Functional walk tests

Intervention type: OTHER
Intervention: Functional walk tests

Intervention type: OTHER
Intervention: 3D analysis of locomotion and posture

Intervention type: OTHER
Intervention: 3D analysis of locomotion and posture

Intervention type: OTHER
Intervention: questionnaires

Intervention type: OTHER
Intervention: questionnaires
Study: NCT03890601

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: A single 15 mL blood draw is planned for this study, as follow:~* 10 mL citrated tube (2 tubes) for APTT, PT, D-Dimers, LA, aCL, aβ2GP1, aβ2GP1-dm1 and TGA~* 5 mL EDTA tube for blood count~During a follow up visit, a 5 ml citrated tube and a 5 mL EDTA tube are collected from each patient for their routine laboratory evaluation. One additional citrated tube will be required to measure thrombin generation and aβ2GP1-dm1.

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: A single 15 mL blood draw is planned for this study, as follow:~* 10 mL citrated tube (2 tubes) for APTT, PT, D-Dimers, LA, aCL, aβ2GP1, aβ2GP1-dm1 and TGA~* 5 mL EDTA tube for blood count~During a follow up visit, a 5 ml citrated tube and a 5 mL EDTA tube are collected from each patient for their routine laboratory evaluation. One additional citrated tube will be required to measure thrombin generation and aβ2GP1-dm1.

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: A single 15 mL blood draw is planned for this study, as follow:~* 10 mL citrated tube (2 tubes) for APTT, PT, D-Dimers, LA, aCL, aβ2GP1, aβ2GP1-dm1 and TGA~* 5 mL EDTA tube for blood count~During a follow up visit, a 5 ml citrated tube and a 5 mL EDTA tube are collected from each patient for their routine laboratory evaluation. One additional citrated tube will be required to measure thrombin generation and aβ2GP1-dm1.
Study: NCT05824793

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: A-PRF+
Description: A-PRF+ contributes to accelerating the healing process, more rapid revascularization, and reducing the risk of inflammation at the graft site. It leads to a decrease in the severity of postoperative complications. Many authors have mentioned platelet concentrates as an effective adjunction that improves the healing of hard and soft tissue and decreases pain, swelling, and trismus. However, there are still some controversial results in the literature. Recently, it has been demonstrated that the production of PRF with lower centrifugal force and lower centrifugal time has more potential to release several growth factors and facilitate more favorable healing at the site of the application when compared to standard PRF. Promoting the healing process after tooth extraction using A-PRF+ aims to manage patient discomfort as well as postoperation complications.
Study: NCT03796793

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound Edge Debridement
Description: Wound debridement is performed using a sharp, circular disposable curette to remove the slough, non-viable tissue and any fibrous tissue down to the vascular base.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Treatment
Description: Standard of Care treatment will include foam dressing and 4 layer compression therapy, changed weekly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care Treatment
Description: Standard of Care treatment will include foam dressing and 4 layer compression therapy, changed weekly.
Study: NCT04528381

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopy
Description: Laparoscopic orchiopexy
Study: NCT01525745

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiosurgery/SBRT
Description: 1, 3 or 5 SBRT treatments

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: 10 consecutive days of standard radiation
Study: NCT01455155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative therapy (art and music therapy)
Description: Creative therapy composed of groups of activities relating to music and art sciences 8 sessions (2 sessions per week for 4 weeks) These activities emphasized on stimulating of cognition, physical, emotion, communication, social relationship, and spiritual domains.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Physical therapy composed of a series of physical therapy program including types of exercises and gait training if possible (5 times/week).
Study: NCT00565240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marvelon
Description: oral contraceptive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuvaring
Description: contraceptive vaginal ring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Aromatase Inhibitors
Study: NCT02779530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: 50 mg po, b.i.d for 6 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo po, b.i.d. for 6 days
Study: NCT03649815

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: App4Independence
Description: The mobile, app-based platform was designed to:~* Help prevent social isolation through personalized prompts, scheduling of activities, and connections to a range of resources relevant to social engagement~* Enhance hopeful and informed engagement in the recovery process through functions that foster resilience and draw on evidence based strategies to enhance wellness (e.g., personalized affirmations; tip sheets; relaxation exercises)~* Encourage and check-in on daily essential activities for patients - addressing memory, attention, and initiation challenges that often occur as a part of this illness~* Provide basic health/safety functionality and track level of wellness~* Provide an anonymous peer-peer online network for strategy sharing~* Provide an ambient sound detector to assist with identifying hallucinations
Study: NCT01061840

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil™
Description: Patients will be treated once a month as long as sufficient material is available for up to 12 doses
Study: NCT03238261

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy and concomitant radiotherapy
Description: Radiotherapy (teletherapy + high or low rate brachytherapy)